What is SeLux DX?
Headquartered in Charlestown, Massachusetts, and founded in 2014, SeLux DX is a pioneering force in the development of precision diagnostics for infectious diseases. The company focuses on transforming clinical outcomes through rapid, accurate diagnostic solutions that address critical gaps in current medical testing protocols. By integrating advanced scientific methodologies with scalable technology, SeLux DX serves as a vital link in the modern healthcare ecosystem, enabling clinicians to make informed, data-driven decisions that directly improve patient care and treatment efficacy.
How much funding has SeLux DX raised?
SeLux DX has raised a total of $176.5M across 5 funding rounds:
Series A
$23.5M
Series B
$25M
Series C
$50M
Debt
$30M
Other Financing Round
$48M
Series A (2018): $23.5M, investors not publicly disclosed
Series B (2018): $25M led by Sands Capital Ventures and RA Capital Advisors
Series C (2022): $50M supported by Schooner Capital, Sands Capital, RA Capital Management, and Northpond Ventures
Debt (2022): $30M featuring Oxford Finance
Other Financing Round (2024): $48M backed by RA Capital Management, Northpond Ventures, and Sands Capital
Key Investors in SeLux DX
RA Capital Management
A multi-stage investment manager focused on evidence-based investing in public and private healthcare and life science companies, utilizing their internal think tank, TechAtlas, to support investment strategies.
Northpond Ventures
A venture firm dedicated to advancing science and technology by identifying and supporting breakthrough innovations that create significant impacts on humanity.
Sands Capital
An established investment firm managing equity mutual funds and public equity markets, providing long-term capital support to growth-oriented enterprises.
What's next for SeLux DX?
With the recent influx of capital, SeLux DX is poised to scale its diagnostic platform and expand its market reach. The strategic focus will likely center on enhancing its R&D capabilities and navigating the complex regulatory pathways required for broader clinical adoption. As the company transitions into this next phase of growth, the continued support from its core investor base will be instrumental in driving the commercialization of its diagnostic suite. The firm remains committed to its mission of revolutionizing infectious disease management through technological excellence and strategic partnerships.
See full SeLux DX company page
